Factor IX gene therapy - Cell GenesysAlternative Names: Haemophilia B gene therapy - Cell Genesys
Latest Information Update: 07 Feb 2003
At a glance
- Originator Cell Genesys
- Developer Cell Genesys; Nonindustrial source
- Class Blood coagulation factors; Coagulants; Gene therapies
- Mechanism of Action Factor IX stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Haemophilia B